Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy

Despite recent advances, the efficacy of androgen/androgen receptor (AR)-targeted therapy remains  limited for many patients with metastatic prostate cancer. This is in part because prostate cancers adaptively switch to the androgen/AR-independent pathway for survival and growth, thereby conferring...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Hao, Xue, Changhui, Mendonca, Janet, Sun, Xiao-Xin, Liu, Qiong, Reardon, Patrick N., Chen, Yingxiao, Qian, Kendrick, Hua, Vivian, Chen, Alice, Pan, Freddy, Yuan, Julia, Dang, Sang, Beer, Tomasz M., Dai, Mu-Shui, Kachhap, Sushant K., Qian, David Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255907/
https://www.ncbi.nlm.nih.gov/pubmed/30478344
http://dx.doi.org/10.1038/s41467-018-07411-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255907/
https://www.ncbi.nlm.nih.gov/pubmed/30478344
http://dx.doi.org/10.1038/s41467-018-07411-7

Ejemplares similares